USPTO Examiner STRACHAN KATE ELIZABETH - Art Unit 3781

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18652657REDUCED PRESSURE THERAPY SYSTEMS AND METHODS INCLUDING AN ANTENNAMay 2024June 2025Allow1410NoNo
17944571Method of Removing Fluid from the Body, and Device ThereforeSeptember 2022July 2024Allow2200NoNo
17940380SYSTEM FOR SHAPING AND IMPLANTING BIOLOGIC INTRAOCULAR STENT FOR INCREASED AQUEOUS OUTFLOW AND LOWERING OF INTRAOCULAR PRESSURESeptember 2022June 2025Allow3300NoNo
17797210A Disposable Flushing and Suction Drainage Tube and Its Operation MethodAugust 2022May 2024Abandon2220NoNo
17758096WRAPPING SHEET AND WRAPPED ABSORBENT ARTICLEJune 2022March 2025Abandon3210NoNo
17785650SYSTEMS AND METHODS FOR OPERATING A WOUND THERAPY DEVICE IN STEALTH MODEJune 2022December 2024Allow3020YesNo
17746815DISPOSABLE ABSORBENT ARTICLE WITH ODOR REDUCING AGENTSMay 2022March 2025Abandon3410NoNo
17743198CRYSTAL INFUSED FEMININE HYGIENE WASHESMay 2022March 2025Abandon3410NoNo
17724845EXTRA-LUMEN ADSORPTION OF VIRAL PATHOGENS FROM BLOODApril 2022September 2024Abandon2910NoNo
17767748BREAST PAD AND METHOD OF MANUFACTUREApril 2022December 2024Abandon3210NoNo
17686597WOUND CARE DEVICE HAVING FLUID TRANSFER AND ADHESIVE PROPERTIESMarch 2022May 2025Allow3840NoYes
17672299Implant Device for Eye Disease for Adjusting Intraocular PressureFebruary 2022July 2023Allow1710NoNo
17590568LIQUID-INDICATING ALARM DIAPER DEVICEFebruary 2022September 2024Abandon3120NoNo
17571693EYE DROP DISPENSER ASSEMBLYJanuary 2022January 2024Abandon2520NoNo
17569929GLAUCOMA TREATMENT DEVICES AND METHODSJanuary 2022April 2023Abandon1510NoNo
17485741MARROW ASPIRATION DEVICE AND METHOD OF USESeptember 2021August 2023Abandon2210NoNo
17399766Unisex Urine Collection AssemblyAugust 2021November 2024Abandon3940NoYes
17417926MULTIFUNCTIONAL CENTRAL SUCTION SYSTEM CAPABLE OF REMOTE MONITORINGJune 2021February 2025Allow4430NoNo
17343937EXTREMITY IRRIGATION DEBRIDEMENT BASINJune 2021May 2024Abandon3540NoNo
17325785SYSTEM FOR SHAPING AND IMPLANTING BIOLOGIC INTRAOCULAR STENT FOR INCREASED AQUEOUS OUTFLOW AND LOWERING OF INTRAOCULAR PRESSUREMay 2021February 2025Allow4521NoNo
17302596AUXILIARY BAND AND METHOD FOR SECURING AN ABSORBENT PAD ONTO A VULVA REGIONMay 2021October 2024Abandon4130YesNo
17306821Automated Fluid Output MonitoringMay 2021April 2024Allow3620YesNo
17302391Body Cavity Access DeviceApril 2021May 2024Abandon3730YesNo
17207718SYSTEMS AND METHODS FOR IMPLANTING A GASTRIC BYPASS DEVICEMarch 2021August 2023Abandon2810NoNo
17202756METHODS OF MONITORING URINARY CATHETER USAGEMarch 2021July 2024Allow4000NoNo
17263092CANNULA FOR THE DRAINAGE OF BLOOD VESSELSJanuary 2021December 2022Abandon2310NoNo
17154983DEVICES, METHODS, AND SYSTEMS FOR IMPROVED ENEMA AND RECTAL IRRIGATION PROCEDURESJanuary 2021June 2024Abandon4030YesNo
17151749Absorbent articles comprising a SBC based hotmelt adhesiveJanuary 2021April 2025Allow5140NoYes
17141009AlgaeAidJanuary 2021June 2023Abandon3010NoNo
17254514Active Agent Delivery Devices and Methods for Using the SameDecember 2020May 2024Abandon4110NoNo
17124415FLUID LEVEL MONITORING SYSTEM FOR PHACOEMULSIFICATION SURGICAL APPLICATIONSDecember 2020July 2024Abandon4340NoNo
17252230AN OSMOTIC ACTUATOR FOR AN INJECTING DEVICE AND AN INJECTION DEVICE COMPRISING SUCH AN OSMOTIC ACTUATORDecember 2020July 2024Abandon4310NoNo
17117297BIDIRECTIONAL VASCULAR CANNULA DEVICEDecember 2020January 2023Allow2510NoNo
17100309HAND TOOL WITH INTEGRATED MICROPUMP AND DRUG RESERVOIR FOR INTRACOCHLEAR DRUG DELIVERYNovember 2020January 2025Abandon4940YesNo
17050768AIR TRAP CHAMBER AND EXTRACORPOREAL CIRCULATION CIRCUITOctober 2020June 2024Allow4310YesNo
17078641Hygiene PadOctober 2020June 2023Abandon3210NoNo
17070187Exhalation Disposal SystemOctober 2020November 2023Abandon3720NoNo
17046023BRIDGE DRESSING WITH FLUID MANAGEMENTOctober 2020December 2023Abandon3840YesNo
17040406Complex Aqua Skin Peeling MachineSeptember 2020September 2024Abandon4820NoNo
17013523MULTI-LAYERED DRESSINGSeptember 2020January 2025Allow5330YesNo
16965986IMPLANTABLE CATHETER ASSEMBLIESJuly 2020October 2023Abandon3920NoNo
16964366SENSOR FOR LOCATING WITHIN A URINARY DRAINAGE BAGJuly 2020January 2024Abandon4221NoNo
16955414IMPLANT DEVICE FOR EYE DISEASE FOR ADJUSTING INTRAOCULAR PRESSUREJune 2020August 2023Allow3840YesNo
16861738Hygiene product in underpants formApril 2020April 2023Abandon3610NoNo
16860517Respiratory Expellant Containment PadApril 2020March 2023Abandon3410NoNo
16647558URINE-DETECTION DEVICE WITH ADHESIVE TAPE AND EMITTER SENSORMarch 2020February 2023Abandon3520NoNo
16748439URINARY CATHETER HAVING AN INJECTION MOLDED TIPJanuary 2020March 2025Abandon6041NoNo
16491542REDUCED PRESSURE THERAPY SYSTEMS AND METHODS INCLUDING AN ANTENNASeptember 2019February 2024Allow5340YesNo
16487915A NOVEL FLEXIBLE MICROFLUIDIC MESHWORK FOR GLAUCOMA SURGERYAugust 2019October 2023Allow5030YesNo
16485240Expandable Percutaneous CannulaAugust 2019February 2025Allow6050YesYes
16484552A VENOVENOUS ECMO (EXTRACORPOREAL MEMBRANE OXYGENATION) CANNULAAugust 2019October 2023Abandon5140NoNo
16513575CONVERTIBLE MULTI-STAGE / BI-CAVAL FEMORAL VENOUS CANNULAJuly 2019December 2022Abandon4120NoNo
16457857Cannula for minimally invasive surgical tricuspid valve repairJune 2019September 2024Abandon6040NoNo
16445799SUCTION TIP FOR GENTLY SUCTIONING A BIOLOGICAL FLUIDJune 2019March 2024Abandon5740YesNo
16442948METHOD AND DEVICE FOR IMPLANTED PORT ALLEVIATIONJune 2019July 2022Abandon3710NoNo
16418729ARTERIAL SHEATH WHICH ALLOWS DISTAL PERFUSION WITHIN A CANNULATED VESSELMay 2019March 2024Allow5811NoNo
16394570Method of Removing Fluid from the Body, and Device ThereforeApril 2019May 2022Allow3710YesNo
16393113CATHETERApril 2019November 2023Allow5520NoYes
16388782SYSTEMS AND METHODS FOR A TELESCOPING DRAINAGE CATHETER AND ASSOCIATED LOCKING MECHANISMSApril 2019December 2023Abandon5521YesNo
16337346METHODS AND SYSTEMS FOR TREATING HYDROCEPHALUSMarch 2019March 2024Allow5930YesYes
16315499GLAUCOMA TREATMENT DEVICES AND METHODSJanuary 2019July 2022Abandon4201NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner STRACHAN, KATE ELIZABETH.

Strategic Value of Filing an Appeal

Total Appeal Filings
6
Allowed After Appeal Filing
4
(66.7%)
Not Allowed After Appeal Filing
2
(33.3%)
Filing Benefit Percentile
92.4%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 66.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Strategic Recommendations

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner STRACHAN, KATE ELIZABETH - Prosecution Strategy Guide

Executive Summary

Examiner STRACHAN, KATE ELIZABETH works in Art Unit 3781 and has examined 60 patent applications in our dataset. With an allowance rate of 35.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 38 months.

Allowance Patterns

Examiner STRACHAN, KATE ELIZABETH's allowance rate of 35.0% places them in the 3% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by STRACHAN, KATE ELIZABETH receive 2.12 office actions before reaching final disposition. This places the examiner in the 71% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by STRACHAN, KATE ELIZABETH is 38 months. This places the examiner in the 13% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +33.2% benefit to allowance rate for applications examined by STRACHAN, KATE ELIZABETH. This interview benefit is in the 84% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 18.2% of applications are subsequently allowed. This success rate is in the 10% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 0.0% of cases where such amendments are filed. This entry rate is in the 1% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 99% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 99% percentile among all examiners. Of these withdrawals, 66.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 80.0% are granted (fully or in part). This grant rate is in the 92% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 42% percentile). This examiner makes examiner's amendments less often than average. You may need to make most claim amendments yourself.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 42% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.